ASX Announcements

ASX Announcements



12 Jan 22: 100+ Pharmacies in Liverpool UK Launch FebriDx Service
24 Dec 21: Section 708A Cleansing Statement
24 Dec 21: Application for Quotation of Securities
24 Dec 21: Notification Regarding Unquoted Securities
24 Dec 21: Notification Regarding Unquoted Securities
24 Dec 21: Change in Substantial Holding
22 Dec 21: Lumos Completes ViraDx™ Development and Provides FebriDx® Regulatory Update
20 Dec 21: Ceasing to be a Substantial Holder
20 Dec 21: Lumos Diagnostics Receives Initial Orders for CoviDx in Canada
18 Nov 21: Release of Shares from Escrow
11 Nov 21: Investor Communication Channels
27 Oct 21: Monthly Activities & Appendix 4C Cash Flow Report
14 Oct 21: Notification of Cessation of Securities
8 Oct 21: Update on Economic Evaluation of FebriDx
6 Oct 21: Economic Evaluation of FebriDx
30 Sept 21: Notification Regarding Unquoted Securities
27 Sept 21: Proposed Issue of Securities
27 Sept 21: Notice of Annual General Meeting & Proxy Form
22 Sept 21: U.S. FDA Deprioritizes EUA Application for CoviDx
20 Sept 21: Notice of Change of Interests of Substantial Holder
14 Sept 21: Appointment of Dr. Jerome Adams as Strategic Health Adviser
1 Sept 21: Change in Substantial Holding
30 Aug 21: FY21 Annual Report
30 Aug 21: FY21 Full Year Results Investor Presentation
30 Aug 21: FY21 Full Year Results Media Release
30 Aug 21: Corporate Governance Statement
30 Aug 21: Appendix 4G
30 Aug 21: FY21 Appendix 4E
23 Aug 21: Release of Shares from Voluntary Escrow
13 Aug 21: FY21 Financial Results Release Date
3 Aug 21: Change in substantial holding – PV
2 Aug 21: Lumos Business Momentum Continues Following ASX Listing
13 Jul 21: Notification of cessation of securities – LDX
9 Jul 21: Becoming a substantial holder – EC
8 Jul 21: Investor Presentation
6 Jul 21: Becoming a substantial holder – ACL
5 Jul 21: Becoming a substantial holder – PV
2 Jul 21: Initial Director’s Interest Notice – BLG
2 Jul 21: Initial Director’s Interest Notice – CR
2 Jul 21: Initial Director’s Interest Notice – LM
2 Jul 21: Initial Director’s Interest Notice – RS
2 Jul 21: Initial Director’s Interest Notice – SL
1 Jul 21: Becoming a substantial holder
1 Jul 21: Becoming a substantial holder – PI
1 Jul 21: Becoming a substantial holder – RPS
1 Jul 21: Media Release – Lumos Diagnostics raises $63 million in ASX IPO
1 Jul 21: Pre-quotation Disclosures
1 Jul 21: Top 20 Holders
1 Jul 21: Distribution Schedule
1 Jul 21: Securities Trading Policy
1 Jul 21: Corporate Governance Statement
1 Jul 21: Long Term Incentive Plan Rules
1 Jul 21: Employee Share Option Plan Rules
1 Jul 21: Constitution
1 Jul 21: Prospectus
1 Jul 21: Appendix 1A and Information Form and Checklist
1 Jul 21: ASX Notice – Admission to Official List


Investor-related questions? Get in touch!